electroCore
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · New Jersey, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
200 Forge Way Ste 205, Rockaway, New Jer...Phone Number
(973) 290-0097Website
www.electrocore.comRevenue
$34.9 MillionStock Symbol
ECORIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
1
1
1
About electroCore
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.Explore more
electroCore Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is electroCore your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if electroCore has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when electroCore launches new products
Click to see if electroCore had a recent Job posting/layoffs
Check out if electroCore is spiking on competitors!
electroCore, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on electroCore recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at electroCore
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once electroCore has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to electroCore
Compare insights from companies similar to electroCore, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
electroCore is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
electroCore is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about electroCore.
electroCore financials insights
Gather financial insights about electroCore, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$50M
2016
Debt
$1.5M
2017
Series B
$70M
2018
Stock Offering
$78M
2020
Share Placement
$25M
Debt
$1M
2025
Private Equity
$1.9M
electroCore Tech Stack
A closer look at the technologies used by electroCore
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company
Promotion
Executive Move
Executive Moves, Promotion
Person-Based
Left Company
Executive Move
Executive Moves, Left Company
electroCore News & Media
electroCore Announces Publication in JAMA Highlighting the Benefits of Adding Quell Electrical Nerve Stimulation to Outpatient Physical Therapy in Fibromyalgia
ROCKAWAY, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the publication of new clinical findings in JAMA Network Open titled, “Transcutaneous Electrical Nerve Stimulation and Pain With Movement in People With Fibromyalgia: A Cluster Randomized Clinical Trial.”electroCore to Present at the LD Micro Invitational XVI Conference on May 18, 2026
ROCKAWAY, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in the LD Micro Invitational XVI Conference being held at the Luxe Sunset Boulevard hotel in Los Angeles, CA. Joshua Lev, Interim President and CFO, will deliver a presentation and host one-on-one meetings throughout the day.electroCore (ECOR) Q1 2026 Earnings Transcript
Thomas Errico: Good afternoon, everyone, and thank you for joining electroCore, Inc.'s first quarter 2026 earnings call. This is the first earnings call since we announced our leadership transition, and I want to take a moment to share how encouraged I am by the progress we have made executing that transition and by the momentum we continue to see across the organization. At the same time, Michael Fox joined us as chief operatingelectroCore Announces First Quarter 2026 Financial Results
First quarter 2026 net sales of $9.6 million, an increase of 43% over $6.7 million in the first quarter 2025
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding electroCore
Sign Up For FreeTo access detailed company insights
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company's current indications are the preventive treatment of cluster headache and migraine, the... Read More
